NCT00269607

Naltrexone Implants as Relapse Prevention

Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Oslo · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants as relapse prevention for patients that are completing treatment for opiate addiction in inpatient (or similarly controlled) settings. Participants in the naltrexone experimental group are prematched in a pairwise fashion with other patients who do not want a naltrexone implant during the first six months after ending inpatient treatment, but who reiceive treatment as usual (TAU) from the Norwegian healthcare system. The hypotheses are that quality of life, depression, opioid use, will be significantly better in the naltrexone group compared to the non at 6-, 12-, and 18-month follow-up. We also hypothesize that the implants can prevent death from opioid overdose up to 6 months after commenced treatment.

Conditions

• Opioid Dependency

Interventions

Type	Name	Description
DRUG	Implantation of naltrexone implants

Timeline

• Start date: 2005-05-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2005-12-23
• Last updated: 2013-12-11